OSE Immunotherapeutics (OSE) Trading update summary

Executive summary

• Cash position at June 30, 2026, was €11.1 million, with runway confirmed through December 2026.

• Flexible bridge equity financing in May 2026 supports operations and is part of a broader financing strategy.

• Publication of H1 2026 financial results postponed amid ongoing financing efforts.

• Active engagement with institutional investors in the US and Europe to extend cash runway beyond 2026.

Financial highlights

• Cash decreased from €17.0 million on March 31, 2026, to €11.1 million on June 30, 2026.

• Current cash and bridge financing estimated sufficient to fund operations through December 2026, excluding potential milestone payments.

Outlook and guidance

• Ongoing efforts to secure additional financing, including potential new partnerships and debt restructuring.

• Cash runway expected through December 2026, with plans to extend further.

• Tedopi's Phase 3 ARTEMIA trial enrolment on track for completion by end of December 2026; futility analysis now expected early 2027.

• Subcutaneous formulation of lusvertikimab expected to reach validation by mid-2027; Phase 2 in chronic pouchitis planned for 2027.